BIOVECTRA ANNOUNCES APPOINTMENT OF GORDON C. MCCAULEY AND STEVEN M. KLOSK TO BOARD

Posted on by BIOVECTRA

Charlottetown, P.E.I. (October 21, 2021) – BIOVECTRA, a leading Canadian biotech and pharmaceutical CDMO has appointed Gordon C. McCauley, President and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex Corporation, to its board of directors.

“Mr. Klosk and Mr. McCauley are innovative executives who offer a wealth of experience to the BIOVECTRA Board of Directors,” says Oliver Technow, CEO of BIOVECTRA.  “BIOVECTRA’s ambitious growth plans will be well-supported through the considerable leadership and expertise that I know each will contribute as directors with our board.”

Gordon McCauley BA, MBA, ICD.D is an accomplished life science executive and investor, having served as president and senior executive of several health care enterprises. As President and CEO of adMare, Mr. McCauley leads its mission to build companies, ecosystems, and talent in the life sciences industry. adMare has over 25 portfolio companies that have attracted more than $1.4 billion of investment with a combined value of over $3 billion.

“I am excited to help as a director with BIOVECTRA,” says Gordon McCauley. “What an excellent example of the type of world-leading companies we can build in Canada. I know BIOVECTRA leadership care deeply about producing high quality products to better serve patient care. I look forward to helping BIOVECTRA scale new heights.”

Steven Klosk BS, JD is a consummate executive of the life sciences industry with over 25 years of experience of CDMO leadership.  Mr. Klosk retired as CEO of Cambrex Corporation in 2020 after leading its sale to Permira, a global private equity firm. During his tenure Cambrex became a leading global and fully integrated supplier of drug substances, drug product and testing services across the entire drug life cycle to both the innovator and generic pharmaceutical markets. The company grew to over 2,000 employees spanning a network of 12 manufacturing and research and development sites in North America and Europe.

“I am thrilled to serve on the board of directors of this thriving CDMO which places care for patients, clients, and its team as integral to BIOVECTRA’s success,” explains Steven Klosk. “This is an exciting time in the life sciences industry, and I look forward to working with the board to help BIOVECTRA reach its optimal success.”

About BIOVECTRA

BIOVECTRA is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients.  Flexibility, creativity, process optimization and compliance are at the heart of our method. With over 550 employees and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.

For additional information, please contact:

Bobbi Jo Walker
Director, Corporate Communications
Telephone: 1-902-200-8550 / Mobile: 1-902-218-7649
Email: [email protected]
www.biovectra.com

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors